Angle PLC Announces Trading Update
ANGLE plc (AIM:AGL, OTCQX:ANPCY), a liquid biopsy company, released its trading update for FY2024. Revenue increased 31% to £2.9 million (from £2.2 million in FY23). The company maintains a strong cash position of £10.4 million as of December 31, 2024, with expected R&D tax credits of £1.4 million in Q1 2025 and £0.8 million in Q3 2025, totaling available cash resources of £12.6 million.
The company's annual loss decreased 30% to approximately £14 million (from £20.1 million in FY23), aligning with guidance. Following strategic focus on pharma services and cost reduction, current cash reserves provide runway into 2026. The company expects higher revenue growth in 2025 compared to 2024, with potential for significant increase over time, supported by progressing pharma contracts and new opportunities.
ANGLE plc (AIM:AGL, OTCQX:ANPCY), un'azienda specializzata in biopsie liquide, ha pubblicato il suo aggiornamento commerciale per l'anno fiscale 2024. I ricavi sono aumentati del 31% raggiungendo 2,9 milioni di sterline (rispetto a 2,2 milioni di sterline nel FY23). L'azienda mantiene una solida posizione di liquidità di 10,4 milioni di sterline al 31 dicembre 2024, con crediti fiscali R&D previsti di 1,4 milioni di sterline nel primo trimestre del 2025 e 0,8 milioni di sterline nel terzo trimestre del 2025, per un totale di risorse di liquidità disponibili di 12,6 milioni di sterline.
La perdita annuale dell'azienda è diminuita del 30% a circa 14 milioni di sterline (rispetto a 20,1 milioni di sterline nel FY23), in linea con le previsioni. A seguito di un focus strategico sui servizi per le industrie farmaceutiche e sulla riduzione dei costi, le attuali riserve di liquidità offrono un margine di manovra fino al 2026. L'azienda prevede una crescita dei ricavi maggiore nel 2025 rispetto al 2024, con il potenziale per un significativo aumento nel tempo, supportato dall'evoluzione dei contratti farmaceutici e da nuove opportunità.
ANGLE plc (AIM:AGL, OTCQX:ANPCY), una empresa de biopsia líquida, publicó su actualización comercial para el año fiscal 2024. Los ingresos aumentaron un 31% alcanzando 2,9 millones de libras (frente a 2,2 millones de libras en el FY23). La empresa mantiene una fuerte posición de efectivo de 10,4 millones de libras a 31 de diciembre de 2024, con créditos fiscales por I+D esperados de 1,4 millones de libras en el primer trimestre de 2025 y 0,8 millones de libras en el tercer trimestre de 2025, totalizando recursos de efectivo disponibles de 12,6 millones de libras.
La pérdida anual de la empresa disminuyó un 30% a aproximadamente 14 millones de libras (frente a 20,1 millones de libras en el FY23), alineándose con la guía. Tras un enfoque estratégico en servicios farmacéuticos y reducción de costos, las reservas de efectivo actuales ofrecen margen hasta 2026. Se espera que la empresa tenga un crecimiento de ingresos más alto en 2025 en comparación con 2024, con potencial para un aumento significativo a lo largo del tiempo, respaldado por la progresión de contratos farmacéuticos y nuevas oportunidades.
ANGLE plc (AIM:AGL, OTCQX:ANPCY), 액체 생검 전문 기업, 2024 회계연도 거래 업데이트를 발표했습니다. 수익이 31% 증가하여 290만 파운드(2023 회계연도의 220만 파운드에서 증가)에 도달했습니다. 이 회사는 2024년 12월 31일 기준으로 1,040만 파운드의 강력한 현금 위치를 유지하고 있으며, 2025년 1분기에는 140만 파운드, 2025년 3분기에는 80만 파운드의 R&D 세금 크레딧이 예상되어 총 1,260만 파운드의 현금 자원을 확보하고 있습니다.
회사의 연간 손실이 30% 감소하여 약 1,400만 파운드(2023 회계연도의 2,010만 파운드에서 감소)로, 가이던스와 일치합니다. 제약 서비스와 비용 절감에 대한 전략적 집중 이후 현재의 현금 준비금은 2026년까지 운영 가능성을 제공합니다. 회사는 2024년과 비교해 2025년 더 높은 수익 성장을 기대하고 있으며, 제약 계약의 진행과 새로운 기회에 의해 장기적으로 상당한 증가가 가능할 것으로 보입니다.
ANGLE plc (AIM:AGL, OTCQX:ANPCY), une société spécialisée dans les biopsies liquides, a publié sa mise à jour commerciale pour l'exercice 2024. Le chiffre d'affaires a augmenté de 31% pour atteindre 2,9 millions de livres (contre 2,2 millions de livres en FY23). La société maintient une solide position de liquidité de 10,4 millions de livres au 31 décembre 2024, avec des crédits d'impôt R&D prévus de 1,4 million de livres au premier trimestre 2025 et de 0,8 million de livres au troisième trimestre 2025, totalisant ainsi des ressources de liquidité disponibles de 12,6 millions de livres.
La perte annuelle de l'entreprise a diminué de 30% pour atteindre environ 14 millions de livres (contre 20,1 millions de livres en FY23), conformément aux indications. Suite à un focus stratégique sur les services pharmaceutiques et la réduction des coûts, les réserves de liquidités actuelles offrent une marge de manœuvre jusqu'en 2026. L'entreprise s'attend à une croissance des revenus plus forte en 2025 par rapport à 2024, avec un potentiel d'augmentation significatif au fil du temps, soutenu par la progression des contrats pharmaceutiques et de nouvelles opportunités.
ANGLE plc (AIM:AGL, OTCQX:ANPCY), ein Unternehmen für Flüssigbiopsien, hat sein Handelsupdate für das Geschäftsjahr 2024 veröffentlicht. Der Umsatz stieg um 31% auf 2,9 Millionen Pfund (von 2,2 Millionen Pfund im Geschäftsjahr 2023). Das Unternehmen weist zum 31. Dezember 2024 eine starke Liquiditätsposition von 10,4 Millionen Pfund auf, mit erwarteten F&E-Steuergutschriften von 1,4 Millionen Pfund im ersten Quartal 2025 und 0,8 Millionen Pfund im dritten Quartal 2025, was insgesamt verfügbare Barmittel in Höhe von 12,6 Millionen Pfund ausmacht.
Der Jahresverlust des Unternehmens sank um 30% auf etwa 14 Millionen Pfund (im Vergleich zu 20,1 Millionen Pfund im Geschäftsjahr 2023), was den Vorgaben entspricht. Nach einer strategischen Fokussierung auf Dienstleistungen für die Pharmaindustrie und Kostensenkung bieten die aktuellen Barmittelreserven Spielraum bis 2026. Das Unternehmen erwartet 2025 ein höheres Umsatzwachstum im Vergleich zu 2024, mit Potenzial für einen signifikanten Anstieg im Laufe der Zeit, unterstützt durch fortschreitende Pharma-Verträge und neue Möglichkeiten.
- Revenue increased 31% to £2.9 million in FY2024
- Annual loss reduced by 30% to £14 million
- Strong cash position of £10.4 million with additional £2.2 million in expected R&D tax credits
- Cash runway extended into 2026
- Higher revenue growth expected in 2025
- Still operating at a significant loss (£14 million in FY2024)
- Dependent on R&D tax credits for cash resources
- Requires Phase 3 clinical trials success to achieve cash flow positivity
Revenue for 2024 expected to be up
Lower cost base going into 2025 with a growing sales pipeline of opportunities
GUILDFORD, SURREY / ACCESS Newswire / January 23, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to provide a trading update in relation to full year 2024 financial results.
Revenues for the year ended 31 December 2024 are expected to be up
The cash position of the Company remains solid, and stronger than market expectations with cash balances of £10.4 million at 31 December 2024, and an R&D tax credit receipt for 2023 of £1.4 million (expected receipt Q1 2025) and for 2024 of c. £0.8 million (expected receipt Q3 2025), giving available cash resources of £12.6 million before additional sales gross margin contributions to the Company. Following the strategic decision to focus on pharma services and reduce the cost base, existing cash balances and tax credits provide the Company with cash runway into 2026. Phase 3 clinical trials secured over the medium term would enable the Company to move into a cashflow positive position.
The loss for the year is expected to be down
2025 revenue growth is expected to be higher compared to 2024. We are pleased with how the sales pipeline is developing and the rate of revenue growth is expected to increase significantly over time.
ANGLE Chief Executive, Andrew Newland, commented:
"We enter 2025 with confidence that our current large pharma contracts are progressing well and have the potential to lead to larger scale opportunities with the same customers coupled with an ability to secure additional new pharma contracts. Despite the challenging market conditions, the adoption of liquid biopsy by large pharma is progressing and ANGLE is uniquely differentiated and well positioned in this growth market."
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Andrew Newland, Chief Executive |
|
|
|
|
|
|
|
|
|
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014).Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.
Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: ANGLE plc
View the original press release on ACCESS Newswire
FAQ
What was ANGLE plc's (ANPCY) revenue growth in 2024?
How much cash does ANGLE plc (ANPCY) have as of December 2024?
What is ANGLE plc's (ANPCY) expected cash runway?
How much did ANGLE plc (ANPCY) reduce its losses in 2024?
What are ANGLE plc's (ANPCY) revenue growth expectations for 2025?
